| Identification | Back Directory | [Name]
TGN 255 | [CAS]
871576-03-3 | [Synonyms]
TGN 255
Flovagatran
PAOGOXGDGABPSC-SGNDLWITSA-N
L-Prolinamide, N-[(phenylmethoxy)carbonyl]-D-phenylalanyl-N-[(1R)-1-borono-4-methoxybutyl]- | [Molecular Formula]
C27H36BN3O7 | [MDL Number]
MFCD16038918 | [MOL File]
871576-03-3.mol | [Molecular Weight]
525.4 |
| Hazard Information | Back Directory | [Uses]
Flovagatran (TGN 255) is a potent and reversible thrombin inhibitor (Ki: 9 nM). Flovagatran can be used in the research of arterial and venous thrombosis[1]. | [in vivo]
Flovagatran (2.5-mg/kg bolus plus 10 mg/kg/h for 90 minutes) produces anticoagulation effects in dogs[1].
| Animal Model: | Chicks[1] | | Dosage: | 1.0-mg/kg bolus and then 4 mg/kg/h for 90 minutes.
2.5-mg/kg bolus and then 10 mg/kg/h for 90 minutes.
5.0-mg/kg bolus and then 20 mg/kg/h for 90 minutes.
| | Administration: | Bolus plus infusion | | Result: | Elevated PD markers, and produced minimal post-operative blood loss. |
| [References]
[1] Nelson DA, et al. Pharmacodynamic and efficacy profile of TGN 255, a novel direct thrombin inhibitor, in canine cardiopulmonary bypass and simulated mitral valve repair. J Extra Corpor Technol. 2008 Jun;40(2):116-22. PMID:18705547 |
|
|